NCT02221310View on ClinicalTrials.gov

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 7, 2011

Primary Completion Date

April 4, 2023

Study Completion Date

April 4, 2023

Conditions
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Gemtuzumab Ozogamicin

Gemtuzumab Ozogamicin 7.5 mg/m\^2/dose given IV over 2 hours once during conditioning

Trial Locations (1)

10595

New York Medical College, Valhalla

Sponsors
All Listed Sponsors
lead

New York Medical College

OTHER